Hip Cartilage Injuries
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients with fibrocartilage injury, i.e., labral injury. This includes patients with a clinical diagnosis of hip impingement (FAI) and congenital developmental dysplasia of the hip (DDH), who have the femoral head in place and have not yet secondary severe degenerative changes (tornis grade 0-2), who have secondary glenoid labral tears confirmed by MRI resulting in hip pain, and who do not have a long history of the disease, and who are suitable for conservative treatment or who refuse surgical treatment and only receive injection therapy; (2) Hyaline cartilage injury, i.e., patients clinically diagnosed with osteoarthritis (OA) of the hip, with a tornis grade of 0-2, suitable for conservative treatment or refusing surgical treatment and receiving only injection therapy; (3) Patients receiving and suitable for conservative treatment; (4) Follow-up is possible; (5) Normal heart function, liver and kidney function, and blood picture; (6) Patients signed the informed consent. Included patients must fulfill any one of items (1) and (2), and must also fulfill items (3) to (6).
Exclusion criteria
Exclusion criteria: (1) FAI secondary to severe hip OA (tornis grade 3) is not suitable for conservative treatment; (2) DDH patients with dislocation of the femoral head, formation of a "false socket", severe deformity of the acetabulum and filling of the acetabulum with adipose and fibrous tissue are not suitable for conservative treatment; (3) Hip OA patients, tornis grade 3 is not suitable for conservative treatment; (4) Systemic arthritis such as rheumatoid and ankylosing spondylitis; (5) Accompanied by serious active infection or serious diseases of heart, liver, kidney and hematopoietic system; (6) Patients do not accept hip puncture injection therapy; (7) Poor compliance. Patients fulfilling any of the items (1) to (7) meet the exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy and success of intra-articular hip injections;Pain level of intra-articular injection operations;Time spent on intra-articular injection;Evaluation of Hip Function and Pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index;Number of intra-articular injections from start of injection to ultrasound confirmation of successful injection;Distance from needle tip to skin edge; | — |
Countries
China
Contacts
Center for Joint Surgery, the First Affiliated Hospital, Army Medical University, Chongqing, China